This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

Pfizer (PFE) stock slips after the company's lower than expected Q1 2025 revenue and the firm seeks acquisitions to boost its ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Dr. Tedros Adhanom Ghebreyesus declares the end of the COVID-19 pandemic, highlighting global vaccination efforts and future ...

Pfizer (NYSE:PFE) is overhauling its cardiometabolic pipeline and weighing acquisitions after an oral weight-loss candidate ...

As the state faces a multimillion dollar measles outbreak in West Texas, the House Public Health Committee passes HB 1586 ...

Viking Therapeutics (VKTX) stock rises as Pfizer (PFE) plans to bolster its pipeline with cardiometabolic and other obesity drugs, through acquisitions. Read more here.

Adding nbUVB phototherapy to oral ritlecitinib improves facial and total body repigmentation in patients with nonsegmental ...

Pfizer (NYSE:PFE) is overhauling its cardiometabolic ... was the right decision for the company after a patient in a dose-optimization study developed liver injury. He added that Pfizer would ...

It is also FDA-authorised under an EUA as a third primary series dose in individuals 12 years old and above who have certain kinds of immunocompromises. The Pfizer/BioNTech bivalent COVID-19 ...

Pfizer took the decision after one of the participants in the dose-optimization studies developed a potentially drug-induced liver injury, which resolved after danuglipron was discontinued.

A decision is expected in the fourth quarter of 2025.